ALMR on Nasdaq

Alamar Biosciences, Inc.

Alamar Biosciences, Inc. is an American laboratory analytical instruments company, incorporated in Delaware.1 It is headquartered in Fremont, California.1 Its shares trade on Nasdaq under the symbol ALMR.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerALMR on Nasdaq1
  • IndustryLaboratory Analytical Instruments1
  • HeadquartersFremont, California1
  • Incorporated inDE2
  • Business address47071 Bayside Parkway, Fremont, Ca 945382
  • Filer category, Emerging growth company2

Corporate structure

Alamar Biosciences, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Alamar Biosciences, Inc.

  • Alamar Biosciences, Inc. Fremont, California

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

Leadership

Who has led Alamar Biosciences, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Yuling Luo2026–now

Chief financial officer

  1. Justin J. McAnear2026–now

Chief operating officer

  1. Shiping Chen2026–now
Board members and other officers (8)

Timeline

  1. Sep 1, 20268-K Executive or director change15
  2. Aug 10, 20268-K Results of operations16
  3. Jul 15, 20268-K Other events17
  4. May 8, 20268-K Results of operations18
  5. Apr 20, 20268-K Bylaws or fiscal year changed; Other events19
  6. Apr 16, 2026New chief executive Yuling Luo becomes CEO5

Calendar

Coming up

  1. Nov 3, 2026 · After the closeReports results for the quarter ending Sep/202620

When it reported results

  1. Aug 10, 2026Reported quarterly or annual results16
  2. May 8, 2026Reported quarterly or annual results18

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

54 filings to the SEC since October 2021: 2 quarterly reports, 5 major events, 23 insider forms, 6 large holders, 18 other. The latest 20:

  1. Oct 14, 2026144 EDGAR
  2. Oct 14, 2026144 EDGAR
  3. Oct 14, 2026144 EDGAR
  4. Oct 14, 2026144 EDGAR
  5. Sep 16, 20264 EDGAR
  6. Sep 16, 20263 EDGAR
  7. Sep 3, 20264 EDGAR
  8. Sep 3, 20263 EDGAR
  9. Sep 1, 20268-K EDGAR
  10. Aug 13, 2026SCHEDULE 13G EDGAR
  11. Aug 11, 2026SCHEDULE 13G EDGAR
  12. Aug 11, 202610-Q EDGAR
  13. Aug 10, 20268-K EDGAR
  14. Jul 15, 20268-K EDGAR
  15. Jul 7, 2026SCHEDULE 13D/A EDGAR
  16. Jul 2, 2026SCHEDULE 13G EDGAR
  17. May 8, 202610-Q EDGAR
  18. May 8, 20268-K EDGAR
  19. Apr 23, 2026SCHEDULE 13D EDGAR
  20. Apr 23, 2026SCHEDULE 13D EDGAR

The 54 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

2 open-market trades by officers, directors and large owners since October 2021: 2 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Apr 20, 2026Naclerio Nicholas10% ownerBuy235,294$17.00$4.0MForm 4
Apr 20, 2026Illumina Innovation Fund II GP, L.L.C.10% ownerBuy235,294$17.00$4.0MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 86. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Sands Capital Alternatives, LLC4,230,926$114.6M18.7%New
Samsara Biocapital, LLC2,480,310$67.2M5.5%New
ARK Investment Management LLC1,373,959$37.2M0.2%New
Braidwell LP1,083,983$29.4M1.1%New
Alliancebernstein L.P.1,003,077$27.2M0.0%New
Hhlr Advisors, Ltd.956,462$25.9M3.1%New
BlackRock, Inc.911,445$24.7M0.0%New
Millennium Management LLC865,764$23.5M0.0%New
Fmr LLC829,424$22.5M0.0%New
Pura Vida Investments, LLC755,909$20.5M55.4%New
Emerald Advisers, LLC647,183$17.5M0.4%New
Artisan Partners Limited Partnership613,744$16.6M0.0%New
Deerfield Management Company, L.P.600,000$16.3M0.2%New
Vanguard Capital Management LLC463,385$12.6M0.0%New
Farallon Capital Management, L.l.c.462,900$12.5M0.1%New
Wellington Management Group Llp457,974$12.4M0.0%New
Emerald Mutual Fund Advisers Trust422,127$11.4M0.4%New
Ameriprise Financial Inc418,965$11.3M0.0%New
Geode Capital Management, LLC330,134$8.9M0.0%New
Woodline Partners LP243,320$6.6M0.0%New
New York State Common Retirement Fund200,758$5.4M0.0%New
Citadel Advisors LLC180,000$4.9M0.0%New
LMR Partners LLP175,000$4.7M0.0%New
Goldman Sachs Group Inc160,029$4.3M0.0%New
Ghisallo Capital Management LLC150,000$4.1M0.1%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Alamar Biosciences, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAlamar Biosciences, Inc.1
  • CIK0002104204
  • Employer ID (EIN)36-48990361
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)3826 Laboratory Analytical Instruments1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address47071 Bayside Parkway, Fremont, CA 945381
  • Phone510-626-98881
  • Shares outstanding69,392,766 as of Jul 31, 20263
  • On EDGAR sinceJan 9, 20261
  • Filings54 in all: 3 (12), 4 (11), 8-K (5), 144 (4), SCHEDULE 13G (3), 10-Q (2), DRS/A (2), EFFECT (2)1
    All 19 form types

    S-1/A (2), SCHEDULE 13D (2), 424B4 (1), 8-A12B (1), CERT (1), DRS (1), POS AM (1), S-1 (1), S-1MEF (1), S-8 (1), SCHEDULE 13D/A (1)

  • Latest filingsQuarterly report (10-Q) Aug 11, 2026
    Latest 8-K (8-K) Sep 1, 2026